Shaily Engineering Plastics Ltd
The Company is engaged in the manufacture and sale of injection moulded precision plastic components, sub-assemblies for various requirements of Original Equipment Manufacturers (OEM).
It also offers secondary operations in plastics like vacuum metalizing, hot stamping, and ultrasonic welding. Its manufacturing facilities are at Savli and Halol, Vadodara, Gujarat. [1]
- Market Cap ₹ 14,580 Cr.
- Current Price ₹ 3,170
- High / Low ₹ 3,615 / 1,660
- Stock P/E 71.6
- Book Value ₹ 169
- Dividend Yield 0.09 %
- ROCE 30.3 %
- ROE 28.2 %
- Face Value ₹ 2.00
Pros
- Company has delivered good profit growth of 48.9% CAGR over last 5 years
Cons
- Stock is trading at 18.8 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 180 | 226 | 246 | 318 | 338 | 336 | 361 | 566 | 600 | 616 | 738 | 921 | 1,045 | |
| 153 | 186 | 205 | 264 | 285 | 277 | 300 | 484 | 512 | 520 | 594 | 665 | 731 | |
| Operating Profit | 26 | 39 | 41 | 54 | 53 | 59 | 60 | 82 | 88 | 96 | 144 | 256 | 314 |
| OPM % | 15% | 17% | 17% | 17% | 16% | 17% | 17% | 15% | 15% | 16% | 20% | 28% | 30% |
| 2 | 3 | 3 | 2 | 2 | 1 | 3 | 9 | 4 | 6 | 7 | 18 | 19 | |
| Interest | 7 | 10 | 8 | 8 | 10 | 11 | 14 | 18 | 19 | 19 | 18 | 17 | 14 |
| Depreciation | 6 | 10 | 13 | 14 | 15 | 18 | 20 | 26 | 33 | 35 | 39 | 45 | 50 |
| Profit before tax | 15 | 21 | 23 | 34 | 30 | 31 | 30 | 46 | 40 | 49 | 95 | 212 | 269 |
| Tax % | 13% | 28% | 32% | 30% | 36% | 23% | 26% | 24% | 25% | 26% | 25% | 24% | |
| 13 | 15 | 16 | 24 | 19 | 24 | 22 | 35 | 30 | 36 | 71 | 161 | 204 | |
| EPS in Rs | 3.13 | 3.72 | 3.81 | 5.74 | 4.63 | 5.67 | 5.29 | 7.66 | 6.53 | 7.88 | 15.43 | 35.10 | 44.31 |
| Dividend Payout % | 13% | 21% | 26% | 26% | 0% | 0% | 0% | 0% | 0% | 13% | 13% | 9% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 21% |
| 3 Years: | 15% |
| TTM: | 23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 49% |
| 3 Years: | 75% |
| TTM: | 63% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 38% |
| 5 Years: | 54% |
| 3 Years: | 108% |
| 1 Year: | 39% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 16% |
| 3 Years: | 18% |
| Last Year: | 28% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves | 70 | 81 | 97 | 116 | 128 | 151 | 174 | 358 | 386 | 422 | 487 | 640 | 768 |
| 83 | 67 | 66 | 107 | 120 | 134 | 200 | 175 | 188 | 209 | 188 | 175 | 178 | |
| 31 | 34 | 29 | 54 | 56 | 88 | 86 | 133 | 101 | 112 | 186 | 246 | 279 | |
| Total Liabilities | 192 | 191 | 200 | 285 | 312 | 381 | 467 | 676 | 685 | 752 | 871 | 1,071 | 1,234 |
| 77 | 97 | 94 | 108 | 145 | 157 | 227 | 329 | 362 | 453 | 477 | 591 | 627 | |
| CWIP | 1 | 0 | 4 | 6 | 5 | 46 | 30 | 29 | 55 | 17 | 18 | 30 | 30 |
| Investments | 26 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 15 | 21 | 11 | 11 | 11 |
| 89 | 93 | 102 | 171 | 161 | 178 | 210 | 309 | 252 | 261 | 365 | 439 | 567 | |
| Total Assets | 192 | 191 | 200 | 285 | 312 | 381 | 467 | 676 | 685 | 752 | 871 | 1,071 | 1,234 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 | 36 | 17 | 5 | 66 | 66 | 22 | 56 | 85 | 74 | 96 | 216 | |
| -38 | 1 | -14 | -26 | -62 | -64 | -82 | -134 | -93 | -92 | -54 | -179 | |
| 32 | -29 | -11 | 20 | -4 | 4 | 53 | 108 | -5 | 5 | -42 | -39 | |
| Net Cash Flow | -1 | 8 | -8 | -0 | 0 | 6 | -6 | 30 | -14 | -13 | -0 | -1 |
| Free Cash Flow | -26 | 8 | -0 | -21 | 2 | 4 | -61 | -60 | -13 | -14 | 27 | 37 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 27% | 103% | 51% | 25% | 145% | 128% | 47% | 76% | 103% | 87% | 77% | 102% |
Ratios
Standalone / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 76 | 58 | 69 | 78 | 64 | 66 | 70 | 64 | 54 | 66 | 73 | 72 |
| Inventory Days | 71 | 67 | 67 | 75 | 75 | 92 | 113 | 114 | 69 | 82 | 121 | 132 |
| Days Payable | 54 | 56 | 48 | 68 | 57 | 96 | 79 | 86 | 48 | 66 | 86 | 74 |
| Cash Conversion Cycle | 93 | 70 | 87 | 85 | 83 | 62 | 105 | 92 | 75 | 82 | 108 | 130 |
| Working Capital Days | 1 | 21 | 24 | 24 | 18 | 4 | 32 | 40 | 3 | 3 | 11 | 12 |
| ROCE % | 16% | 19% | 19% | 21% | 17% | 15% | 13% | 14% | 10% | 11% | 17% | 30% |
Insights
In beta| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Mar 2028 (P) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Machine Utilization (Across Plants) % |
|
||||||||||
| Volume of Polymers Processed MT |
|||||||||||
| Number of Employees Count |
|||||||||||
| Number of Injection Molding Machines Count |
|||||||||||
| Export Revenue Share % |
|||||||||||
| Pen Injector Production Capacity Millions of pens |
|||||||||||
| Pen Injector Volume (Devices Sold) Millions of devices |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Audio recording of earnings call held on 30 October 2026 uploaded; transcript to follow.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
- Submission of Investor Presentation for the quarter ended on September 30, 2026
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
- Intimation of allotment of 1300 ESOPs by the Company
-
Unaudited Financial Results For The Quarter Ended On September 30, 2026
- Auditor issued limited review report for Q2 FY2026 standalone and consolidated results ended 30 September 2026.
-
Board Meeting Outcome for Intimation Of Outcome Of Board Meeting
- Board approved unaudited standalone and consolidated results for quarter and half-year ended 30 September 2026.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Concalls
-
Oct 2026PPT REC
-
Aug 2026Transcript PPT REC
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Feb 2024PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021Transcript
-
Aug 2021PPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript
-
Nov 2020Transcript
-
Aug 2020Transcript
-
Jul 2020Transcript
-
Nov 2019PPT
-
Mar 2018Transcript PPT
-
Jan 2016PPT
Business Segments:[1]
a) Consumer:
Home Furnishings, FMCG Packaging,
LED Lights, Toys, Carbon Steel Furniture.
b) Industrial:
Automotive Components, Appliances,
High-Performance Engineering Components, Consumer Electronics, Semiconductor Trays
and Packaging.
c) Healthcare:
Platform Devices, Drug Delivery
Devices, Pharma Packaging.